Year After Acquisition, Perrigo Waits For US Decision On HRA’s OTC Oral Contraceptive Switch
Wait will be as long as another three months to learn whether HRA will have approval to market OTC a product Perrigo estimates will have $100m in annual sales.
You may also be interested in...
At helm nearly five years with Perrigo continuing to navigate comprehensive turnaround with a target of returning to its historical profile of driving volume sales while keeping costs lower than is brand-name OTC drug competitors, he’s leaving at end of July.
Day after releasing Q4 and full-year results, Perrigo announced launch of next chapter in its “3/5/7” makeover strategy. It reached annual growth of 3% for top line revenues in phase 1, aims for 5% operating income and 7% earnings per share growth in phase 2.
Whether FDA handling of HRA Pharma’s OTC switch NDA for 0.075-mg norgestrel continues along normal arc is question which prompts concerns. “I hope that they don't make the same mistakes that were made back on the Plan B,” says Susan Wood, an associate professor at George Washington University School of Public Health and a former FDA office director.